Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated)

For adults aged 18 to 64, the standard dosage of a quadrivalent influenza vaccine containing the B/Phuket/3073/2013 antigen is a single 0.5 mL intramuscular injection. Each 0.5 mL dose typically contains 15 micrograms (mcg) of the hemagglutinin (HA) antigen from each of the four virus strains, totaling 60 mcg of HA per dose.

For adults aged 65 and older, a 'High-Dose' version may be administered. In these formulations (such as Fluzone High-Dose), the concentration of the B/Phuket/3073/2013 antigen is increased to 60 mcg per strain (240 mcg total HA per 0.7 mL dose). This higher dose is intended to elicit a more robust immune response in older adults who may not respond as strongly to the standard dose. Your healthcare provider will determine which formulation is appropriate based on your age and health status.

Pediatric dosing for vaccines containing the Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen is strictly categorized by age:

• Children 6 months through 35 months: Depending on the specific vaccine brand, the dose may be 0.25 mL or 0.5 mL.
• Children 3 years through 17 years: The standard dose is 0.5 mL administered intramuscularly.
• Priming Dose Requirement: Children aged 6 months through 8 years who have not previously received at least two doses of influenza vaccine (at any time) require two doses in the current season, spaced at least 4 weeks apart. This 'prime-boost' strategy ensures the child's immune system is sufficiently prepared to recognize the Phuket strain and other components. If the child has already received two lifetime doses, a single annual dose is usually sufficient.

Renal Impairment

No dosage adjustments are required for patients with renal impairment. The antigen is not cleared by the kidneys in a manner that would lead to accumulation or toxicity. However, patients on dialysis should ideally be vaccinated on non-dialysis days to ensure the best possible immune response.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment. The liver does not play a role in the clearance of the inactivated hemagglutinin protein.

Elderly Patients

As noted, elderly patients (65+) are often encouraged to receive the high-dose or adjuvanted versions of the vaccine to ensure adequate protection against the B/Phuket strain. Standard doses are safe but may be less effective in this demographic.

This medication is administered exclusively by a healthcare professional. It is given as an intramuscular (IM) injection.

• Site Selection: In adults and older children, the preferred site is the deltoid muscle of the upper arm. In infants and small children, the anterolateral aspect of the thigh (vastus lateralis muscle) is preferred due to muscle mass.
• Preparation: The vaccine should be shaken well before administration to ensure a uniform suspension. It should be inspected visually for particulate matter or discoloration. The vaccine should be at room temperature before injection to reduce discomfort.
• Administration: The healthcare provider will use a needle of appropriate length (usually 1 to 1.5 inches for adults) to ensure the antigen reaches the muscle tissue rather than the subcutaneous fat.
• Storage: The vaccine must be stored under refrigeration between 2°C and 8°C (36°F to 46°F). It must never be frozen. Exposure to freezing temperatures destroys the structure of the hemagglutinin antigen, rendering it ineffective.

Because the flu vaccine is typically a single annual dose, a 'missed dose' refers to failing to get vaccinated before the flu season begins. If you miss your scheduled appointment, you should reschedule as soon as possible. It is beneficial to receive the vaccine even late in the season (January or February), as Influenza B strains like Phuket/3073/2013 often circulate later in the spring than Influenza A strains.

An overdose is highly unlikely as the medication is administered by healthcare professionals in single-dose increments. In the event of an accidental double dose, the primary risk is an increase in local injection site reactions (swelling, pain) or systemic symptoms like fever. There is no specific 'antidote' for a vaccine overdose; treatment is supportive (e.g., acetaminophen for fever). If you suspect an error in administration, contact your healthcare provider immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer this vaccine without medical guidance.

Side effects from the Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen are generally mild and are a sign that the immune system is responding to the antigen. These typically appear within 6 to 24 hours of administration and resolve within 48 to 72 hours.

• Injection Site Pain: The most common report, described as a dull ache or soreness in the arm where the shot was given. This occurs in up to 65% of recipients.
• Erythema and Swelling: Redness and slight hardening (induration) at the site of injection.
• Fatigue and Malaise: A general feeling of tiredness or 'feeling under the weather.'
• Headache: Mild to moderate tension-type headache.
• Myalgia: Generalized muscle aches, which can feel similar to the early stages of a cold.

• Low-Grade Fever: A temperature usually below 101°F (38.3°C). This is more common in children receiving their first doses.
• Nausea: Mild stomach upset or loss of appetite.
• Shivering/Chills: Brief episodes of feeling cold as the body's temperature regulation reacts to the immune stimulus.
• Arthralgia: Joint pain, particularly in the shoulders or knees.

• Lymphadenopathy: Swelling of the lymph nodes, usually in the armpit (axilla) on the side of the injection. This is a normal part of the immune response but can be concerning if not understood.
• Syncope: Fainting, particularly in adolescents, often due to a vasovagal response to the needle rather than the antigen itself.
• Urticaria: Hives or a generalized itchy rash, which may indicate a mild allergic sensitivity.

While extremely rare, serious reactions can occur.

> Warning: Stop taking Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the throat or tongue, rapid heartbeat, and a sharp drop in blood pressure. This typically occurs within minutes of injection.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. The risk is estimated at 1 to 2 additional cases per million doses. Seek help if you feel tingling or weakness starting in your legs and moving upward.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Severe, persistent pain and limited range of motion in the shoulder, caused by the needle being injected too high or too deep into the joint space rather than the muscle.
• Facial Palsy (Bell's Palsy): Temporary weakness or paralysis of the facial muscles has been reported in very rare instances, though a definitive causal link is often debated.

There are no known long-term adverse effects associated with the B/Phuket/3073/2013 antigen. The protein is degraded by the body within days. The only 'long-term' effect is the presence of protective antibodies, which is the intended therapeutic goal. Studies following vaccine recipients for years have shown no increase in autoimmune diseases or chronic health conditions linked to the annual flu shot.

There are currently no FDA Black Box Warnings for Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated). It is considered safe for the general population, including those with stable chronic health conditions.

Report any unusual symptoms or side effects that persist longer than three days to your healthcare provider. You may also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving a vaccine containing the Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen, it is vital to understand that while the vaccine is highly safe, it is a biological product that interacts with the immune system. It does not provide 100% protection against all strains of the flu, only those contained in the specific formulation. Furthermore, it takes approximately two weeks after the injection for the body to develop a full antibody response. During this 'window,' you remain susceptible to infection.

No FDA black box warnings for Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Individuals with a history of severe allergic reaction (anaphylaxis) to any component of the vaccine, including the Phuket antigen, formaldehyde, or egg proteins (ovalbumin), should generally not receive the vaccine. Healthcare providers should have emergency equipment (epinephrine) available during administration.
• Guillain-Barré Syndrome (GBS): If you have ever had GBS within 6 weeks of a previous influenza vaccination, your doctor will carefully weigh the risks and benefits of giving you this antigen. In some cases, the risk of a GBS recurrence may outweigh the benefit of flu protection.
• Acute Febrile Illness: If you have a moderate to severe illness with a fever, vaccination should typically be delayed until you have recovered. A minor cold or low-grade fever is usually not a reason to delay the shot, but discuss this with your clinician.
• Immunocompromised Patients: Individuals with weakened immune systems (due to HIV, cancer, or immunosuppressive drugs) may have a reduced immune response to the antigen. While the vaccine is safe for these individuals (because it is inactivated), it may not provide the same level of protection as it does in healthy individuals.
• Bleeding Disorders: For patients with hemophilia or those on anticoagulant therapy (blood thinners), there is a risk of hematoma (bruising/bleeding) at the injection site. A fine-gauge needle and firm pressure should be applied for at least two minutes post-injection.

There are no routine lab tests (like blood counts or liver function tests) required after receiving this antigen. However, patients should be observed for at least 15 minutes after the injection to monitor for immediate allergic reactions or syncope (fainting).

The Influenza B Virus B/phuket/3073/2013 antigen has no known effect on the ability to drive or operate heavy machinery. However, if you experience dizziness or a vasovagal response immediately after the injection, you should wait until these symptoms resolve before driving.

There is no direct interaction between alcohol and the Phuket/3073/2013 antigen. However, excessive alcohol consumption can suppress the immune system and may theoretically reduce the effectiveness of the vaccine's antibody production. It is generally advisable to avoid heavy drinking for 48 hours post-vaccination to allow the immune system to focus on the antigen.

As this is a single-dose administration, 'discontinuation' is not applicable in the traditional sense. However, if you experience a severe reaction to this year's vaccine, you may be advised to avoid future vaccines containing this specific strain or to switch to a different type of formulation (such as an egg-free or recombinant version).

> Important: Discuss all your medical conditions, including any history of allergies or neurological issues, with your healthcare provider before starting Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would result in a fatal interaction; however, certain combinations are avoided to ensure vaccine efficacy:

• Other Live Vaccines (Simultaneous Administration): While inactivated antigens like Phuket/3073/2013 can generally be given with other inactivated vaccines, caution is sometimes advised when giving multiple vaccines at once to ensure that the immune response to one does not interfere with the other. However, current CDC guidelines state that most vaccines can be given on the same day at different injection sites.

• Immunosuppressive Therapies: Drugs such as high-dose corticosteroids (e.g., prednisone >20mg/day), chemotherapy agents, and TNF-inhibitors (e.g., adalimumab, etanercept) can significantly blunt the immune response to the Phuket/3073/2013 antigen. The clinical consequence is reduced vaccine efficacy, leaving the patient at higher risk for the flu despite being vaccinated. Timing the vaccine between cycles of immunosuppression is often recommended.
• B-cell Depleting Therapies: Medications like rituximab, which deplete the B-cells responsible for making antibodies, can render the vaccine almost entirely ineffective if given too close to the drug dose. Ideally, the vaccine should be administered at least 4 weeks before the next rituximab dose.

• Antivirals (Oseltamivir, Zanamivir): Since this is an inactivated vaccine, antiviral medications do not interfere with its action. This is a common misconception; antivirals only interfere with the Live Attenuated Influenza Vaccine (nasal spray).
• Statins: Some studies suggest that patients on chronic statin therapy may have slightly lower antibody titers following influenza vaccination. However, this is not a reason to stop statins; the vaccine still provides significant protection.

• Egg Proteins: Most formulations of the Phuket/3073/2013 antigen are grown in eggs. While the antigen itself is purified, trace amounts of ovalbumin may remain. Patients with a history of severe egg allergy should be vaccinated in a medical setting or use an egg-free (recombinant or cell-culture) version of the vaccine.
• Dairy/Caffeine/Grapefruit: There are no known interactions between these food items and the influenza antigen.

• Echinacea and Elderberry: These supplements are often used to 'boost' the immune system. While there is no evidence they interfere with the vaccine, they have not been clinically studied in combination with the Phuket/3073/2013 antigen.
• High-dose Vitamin C: No known interaction, though it will not significantly improve the vaccine's efficacy.

• False Positive HIV/HCV/HTLV1 Tests: In rare cases, the immune response to the influenza vaccine can cause a transient false-positive result on certain enzyme-linked immunosorbent assays (ELISA) for HIV-1, Hepatitis C, and HTLV-1. If you have a positive screening test shortly after a flu shot, a more specific confirmatory test (like a Western Blot or PCR) should be performed.
• Blood Donation: Most blood centers require a short waiting period (usually 48 hours) after receiving the vaccine to ensure you do not develop a fever or other symptoms that would disqualify the donation.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. It is especially important to mention if you are undergoing any treatment that affects your immune system.

Conditions where Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated) must NEVER be used:

• Severe Allergic Reaction (Anaphylaxis) to Previous Flu Vaccine: If a patient has experienced a life-threatening reaction to any influenza vaccine in the past, regardless of the specific strain, they should not receive this antigen. The risk of a repeat, potentially fatal reaction outweighs the benefit of immunization.
• Severe Allergy to Vaccine Components: This includes a known, severe allergy to formaldehyde (used for inactivation), polysorbate 80 (used as a stabilizer in some brands), or neomycin/polymyxin (trace antibiotics used in manufacturing).
• Infants under 6 months of age: The safety and efficacy of the Phuket/3073/2013 antigen have not been established in infants younger than 6 months. Furthermore, their immune systems are generally unable to mount a sufficient response to the inactivated antigen, and they rely on maternal antibodies for protection.

Conditions requiring careful risk-benefit analysis:

• History of Guillain-Barré Syndrome (GBS): As mentioned, if GBS occurred within 6 weeks of a previous flu shot, the decision to vaccinate should be made cautiously. If the patient is at very high risk for severe flu complications, the doctor may still recommend it.
• Moderate or Severe Acute Illness: Vaccination should be deferred until the illness resolves to avoid diagnostic confusion between the symptoms of the illness and the side effects of the vaccine.
• Egg Allergy (Non-Anaphylactic): According to current CDC guidelines, most people with egg allergies (including those who only get hives) can receive any flu vaccine. However, if the allergy is severe (respiratory distress, lightheadedness), the vaccine should be administered in a setting where a physician can manage a reaction.

There is a potential for cross-sensitivity among different brands of influenza vaccines. If a patient is allergic to one brand of quadrivalent vaccine, they may be allergic to others that use the same manufacturing process or stabilizers. However, they may be able to tolerate an egg-free or preservative-free version. Always consult an allergist if cross-sensitivity is suspected.

> Important: Your healthcare provider will evaluate your complete medical history, including all past vaccine reactions, before prescribing or administering Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen (formaldehyde Inactivated).

Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen is strongly recommended for pregnant women.

• Safety: Extensive data from decades of use of inactivated flu vaccines show no increased risk of miscarriage, birth defects, or pregnancy complications.
• Benefits: Pregnancy changes the immune system, heart, and lungs, making pregnant women more susceptible to severe illness from Influenza B. Vaccination protects both the mother and the fetus.
• Passive Immunity: Antibodies produced by the mother cross the placenta and provide critical protection to the newborn for several months after birth, a period when the infant is too young to be vaccinated themselves.
• Category: Usually classified as Pregnancy Category B or C depending on the specific brand, though the CDC considers it a standard of care.

The Phuket/3073/2013 antigen is safe for use during breastfeeding. The inactivated proteins do not pass into breast milk, but the protective antibodies (IgA and IgG) do. This 'maternal immunization' helps protect the nursing infant from respiratory infections. There is no need to delay or stop breastfeeding after receiving the vaccine.

• Approved Age: Approved for children 6 months and older.
• Growth Effects: There is no evidence that the influenza antigen affects growth or development.
• Febrile Seizures: In very rare cases, children receiving the flu vaccine at the same time as the pneumococcal vaccine (PCV13) may have a slightly increased risk of febrile seizures (seizures caused by fever). These are usually harmless but should be discussed with a pediatrician.

Patients over 65 are at the highest risk for death and hospitalization from Influenza B/Phuket.

• Immunosenescence: Because the immune system weakens with age, seniors may produce fewer antibodies in response to the standard 15 mcg dose.
• High-Dose Recommendation: As discussed, the 60 mcg high-dose formulation is often preferred for this population to ensure adequate protection.
• Safety: The side effect profile in seniors is similar to younger adults, though local injection site reactions may be slightly more pronounced with the high-dose version.

No dose adjustment is needed. Patients with chronic kidney disease (CKD) are considered high-priority for vaccination because they are at increased risk for secondary bacterial pneumonia following a flu infection.

No dose adjustment is needed. The antigen does not undergo hepatic metabolism and does not affect liver enzymes. It is safe for patients with cirrhosis or hepatitis.

> Important: Special populations require individualized medical assessment. Always inform your provider of your pregnancy status or any chronic health conditions.

Influenza B Virus B/phuket/3073/2013 Hemagglutinin Antigen works as an active immunizing agent. The 'active' part of the name refers to the fact that the body must actively produce its own immune response. The hemagglutinin (HA) protein on the surface of the inactivated virus is the key 'key' that the live virus uses to unlock human cells. By introducing the purified HA protein from the Phuket/3073/2013 strain, the vaccine induces the production of neutralizing antibodies. These antibodies bind to the antigenic sites on the HA head (specifically the globular domain), which prevents the virus from binding to the sialic acid receptors on the host's respiratory cells. Without attachment, the virus cannot undergo endocytosis or release its viral RNA into the host cell, effectively halting the infection process.

• Dose-Response: There is a clear dose-response relationship; higher doses (as seen in geriatric formulations) lead to higher hemagglutination-inhibition (HI) titers.
• Onset of Effect: Protective antibody levels are typically reached 10 to 14 days after administration.
• Duration of Effect: Protection generally lasts for 6 to 12 months. Antibody titers against the Phuket strain typically decline by 50% within a year, necessitating annual revaccination.
• Tolerance: There is no 'tolerance' in the pharmacological sense, but 'original antigenic sin' is a phenomenon where the body's first exposure to a flu strain influences its response to future vaccines.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life (Antigen) | Hours to Days (Degraded) |

| Half-life (Antibodies) | ~21-28 days (IgG) |

| Tmax (Antibody) | 14 Days |

| Metabolism | Proteolysis in APCs |

| Excretion | Cellular turnover |

• Molecular Structure: The antigen is a trimeric glycoprotein. Each monomer consists of two subunits, HA1 and HA2, linked by a disulfide bond.
• Inactivation: Formaldehyde (CH2O) is used to create methylene cross-links between amino groups in the viral proteins, 'freezing' the structure and destroying infectivity.
• Solubility: Formulated as a sterile aqueous suspension.

This antigen is classified as an Inactivated Viral Vaccine. It is part of the Quadrivalent Influenza Vaccine (QIV) class. Related antigens often co-administered include Influenza A (H1N1), Influenza A (H3N2), and another Influenza B strain (typically from the Victoria lineage).